[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596362":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":25,"locations":34,"responsibleParty":52,"collaborators":55,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":18,"enrollmentInfo":72,"targetDuration":18,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":18,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"CBT4CBT-Buprenorphine","EXPERIMENTAL",[12],"Behavioral: CBT4CBT-Buprenorphine",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"BEHAVIORAL","CBT4CBT-Buprenorphine is an evidence-based, Internet-delivered cognitive behavioral therapy program for individuals prescribed buprenorphine by a medical provider. It includes eight 30-minute modules.",[9],null,[20,23],{"name":21,"affiliation":5,"role":22},"Amber M Jarnecke, PhD","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":5,"role":22},"Rachel Tomko, PhD",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Amber Anderson, BA","CONTACT","843-876-3115","anderamb@musc.edu",{"name":32,"role":28,"phone":29,"phoneExt":18,"email":33},"Kevin Branson, MA","bransonk@musc.edu",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Charleston","South Carolina","29412","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-79.93275,32.77632,{"lat":46,"lon":45},[49],{"name":50,"role":28,"phone":29,"phoneExt":18,"email":51},"Amber Jarnecke, PhD","jarnecka@musc.edu",{"type":22,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Amber Jarnecke","Associate Professor-Faculty",[56,59],{"name":57,"class":58},"National Institute on Drug Abuse (NIDA)","NIH",{"name":60,"class":58},"National Institutes of Health (NIH)","100596362","social-functioning-in-opioid-use-disorder-100596362",false,"NCT07044466","Social Functioning in Opioid Use Disorder","Real-world Assessment of Social Functioning During OUD Treatment: Integrating Reports From Patients and Their Concerned Significant Others","OUD","Inclusion Criteria:\n\n* Any sex or gender; any race or ethnicity; aged 18 years or older\n* Patient participants must meet DSM-5 diagnostic criteria for current (i.e., past 12 months) OUD (assessed via the Quick Structured Clinical Interview for DSM-5; Quick SCID)\n* Patient participants must be on medication for opioid use disorder (MOUD), as prescribed by their provider, for no more than 12 weeks prior to study initiation\n* Patient participants must be in treatment at a clinic in South Carolina\n* Concurrent substance use disorders (e.g., alcohol, cannabis) for the patient participant are acceptable, provided opioids are the patient participant's primary substance of choice\n* Patient participants must identify a CSO participant who consents to participation in the study as well\n\nExclusion Criteria:\n\n* Moderate-to-severe opioid withdrawal as defined by a score of ≥21 on the Subjective Opioid Withdrawal Scale\n* Meeting DSM-5 criteria for a history of or current psychotic or bipolar disorders\n* Current suicidal or homicidal ideation and intent; participants who present a serious suicide risk are likely to require hospitalization during the study and they will be referred clinically\n* CSO participants meeting DSM-5 criteria for opioid use disorder or any other substance use disorder, excepting tobacco use disorder, mild cannabis use disorder, and mild alcohol use disorder\n* Severe interpersonal violence in the past six months between the patient and the CSO, as defined by an adapted version of the Conflict Tactics Scaled Revised (CTS-2)\n* Pregnancy for patient participants\n* Prisoners, institutional individuals, and children will not be recruited for this study.",true,"ALL","18 Years",{"count":73,"type":74},230,"ESTIMATED","INTERVENTIONAL",[77],"NA","Problems with social functioning are core to opioid use disorder (OUD), though specific, modifiable social functioning targets and how they relate to OUD treatment outcomes are poorly understood. This study will utilize both data from both patients with OUD and their concerned significant other (CSO) to examine associations between specific social functioning metrics and OUD treatment outcomes. Findings from this study will inform future precision-medicine approaches for people with OUD, a population in significant need of enhanced treatment approaches to combat opioid morbidity and mortality.",[80],"Opioid Use Disorder","2026-08-13",{"date":83,"type":84},"2026-08-17","ACTUAL",{"date":81,"type":84},{"date":87,"type":74},"2029-08-31",{"name":5,"class":6},1]